Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Accumulated Expenses (2016 - 2022)

Usana Health Sciences has reported Accumulated Expenses over the past 10 years, most recently at $32.4 million for Q1 2022.

  • Quarterly Accumulated Expenses rose 0.56% to $32.4 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $32.4 million through Jan 2022, up 0.56% year-over-year, with the annual reading at $32.4 million for FY2022, 0.56% up from the prior year.
  • Accumulated Expenses was $32.4 million for Q1 2022 at Usana Health Sciences, up from $32.2 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $33.7 million in Q4 2018 and troughed at $26.2 million in Q4 2019.
  • The 4-year median for Accumulated Expenses is $32.3 million (2021), against an average of $31.1 million.
  • Year-over-year, Accumulated Expenses surged 47.13% in 2018 and then decreased 22.41% in 2019.
  • A 4-year view of Accumulated Expenses shows it stood at $33.7 million in 2018, then decreased by 22.41% to $26.2 million in 2019, then rose by 23.07% to $32.2 million in 2021, then grew by 0.56% to $32.4 million in 2022.
  • Per Business Quant, the three most recent readings for USNA's Accumulated Expenses are $32.4 million (Q1 2022), $32.2 million (Q1 2021), and $26.2 million (Q4 2019).